Page 60 - Read Online
P. 60

Page 26 of 30                 Raffetto et al. Vessel Plus 2021;5:36  https://dx.doi.org/10.20517/2574-1209.2021.16

                    veins. J Vasc Surg 2009;50:1149-54.  DOI  PubMed
               121.      Morla AO, Mogford JE. Control of smooth muscle cell proliferation and phenotype by integrin signaling through focal adhesion
                    kinase. Biochem Biophys Res Commun 2000;272:298-302.  DOI  PubMed
               122.      Karsdal MA, Larsen L, Engsig MT, et al. Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta
                    controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem 2002;277:44061-7.  DOI
                    PubMed
               123.      Mao D, Zhang Y, Lu H, Zhang H. Molecular basis underlying inhibition of metastasis of gastric cancer by anti-VEGFa treatment.
                    Tumour Biol 2014;35:8217-23.  DOI  PubMed
               124.      Zhang H, Chalothorn D, Jackson LF, Lee DC, Faber JE. Transactivation of epidermal growth factor receptor mediates catecholamine-
                    induced growth of vascular smooth muscle. Circ Res 2004;95:989-97.  DOI  PubMed
               125.      Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol 2001;13:555-62.  DOI  PubMed
               126.      Almeida EA, Ilic D, Han Q, et al. Matrix survival signaling: from fibronectin via focal adhesion kinase to c-Jun NH(2)-terminal
                    kinase. J Cell Biol 2000;149:741-54.  DOI  PubMed  PMC
               127.      Ilic D, Almeida EA, Schlaepfer DD, Dazin P, Aizawa S, Damsky CH. Extracellular matrix survival signals transduced by focal
                    adhesion kinase suppress p53-mediated apoptosis. J Cell Biol 1998;143:547-60.  DOI  PubMed  PMC
               128.      Levkau B, Kenagy RD, Karsan A, et al. Activation of metalloproteinases and their association with integrins: an auxiliary apoptotic
                    pathway in human endothelial cells. Cell Death Differ 2002;9:1360-7.  DOI  PubMed
               129.      Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ
                    Res 2003;92:827-39.  DOI  PubMed
               130.      Somerville RP, Oblander SA, Apte SS. Matrix metalloproteinases: old dogs with new tricks. Genome Biol 2003;4:216.  DOI
                    PubMed  PMC
               131.      Mannello F, Luchetti F, Falcieri E, Papa S. Multiple roles of matrix metalloproteinases during apoptosis. Apoptosis 2005;10:19-24.
                    DOI  PubMed
               132.      Bond M, Murphy G, Bennett MR, et al. Localization of the death domain of tissue inhibitor of metalloproteinase-3 to the N terminus.
                    Metalloproteinase inhibition is associated with proapoptotic activity. J Biol Chem 2000;275:41358-63.  DOI  PubMed
               133.      Kwan JA, Schulze CJ, Wang W, et al. Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is
                    capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro. FASEB J 2004;18:690-2.  DOI  PubMed
               134.      Nagareddy PR, Chow FL, Hao L, et al. Maintenance of adrenergic vascular tone by MMP transactivation of the EGFR requires PI3K
                    and mitochondrial ATP synthesis. Cardiovasc Res 2009;84:368-77.  DOI  PubMed
               135.      Chew DK, Conte MS, Khalil RA. Matrix metalloproteinase-specific inhibition of Ca2+ entry mechanisms of vascular contraction. J
                    Vasc Surg 2004;40:1001-10.  DOI  PubMed
               136.      Raffetto JD, Barros YV, Wells AK, Khalil RA. MMP-2 induced vein relaxation via inhibition of [Ca2+]e-dependent mechanisms of
                    venous smooth muscle contraction. Role of RGD peptides. J Surg Res 2010;159:755-64.  DOI  PubMed  PMC
               137.      Waitkus-Edwards KR, Martinez-Lemus LA, Wu X, et al. Alpha(4)beta(1) Integrin activation of L-type calcium channels in vascular
                    smooth muscle causes arteriole vasoconstriction. Circ Res 2002;90:473-80.  DOI  PubMed
               138.      Macfarlane SR, Seatter MJ, Kanke T, Hunter GD, Plevin R. Proteinase-activated receptors. Pharmacol Rev 2001;53:245-82.
                    PubMed
               139.      Hamilton JR, Nguyen PB, Cocks TM. Atypical protease-activated receptor mediates endothelium-dependent relaxation of human
                    coronary arteries. Circ Res 1998;82:1306-11.  DOI  PubMed
               140.      Raffetto JD, Ross RL, Khalil RA. Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K+
                    channels: relevance to varicose vein formation. J Vasc Surg 2007;45:373-80.  DOI  PubMed  PMC
               141.      Goerge T, Barg A, Schnaeker EM, et al. Tumor-derived matrix metalloproteinase-1 targets endothelial proteinase-activated receptor 1
                    promoting endothelial cell activation. Cancer Res 2006;66:7766-74.  DOI  PubMed
               142.      Tarin C, Gomez M, Calvo E, Lopez JA, Zaragoza C. Endothelial nitric oxide deficiency reduces MMP-13-mediated cleavage of
                    ICAM-1 in vascular endothelium: a role in atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:27-32.  DOI  PubMed
               143.      Louboutin JP, Agrawal L, Reyes BA, Van Bockstaele EJ, Strayer DS. HIV-1 gp120-induced injury to the blood-brain barrier: role of
                    metalloproteinases 2 and 9 and relationship to oxidative stress. J Neuropathol Exp Neurol 2010;69:801-16.  DOI  PubMed  PMC
               144.      Thanabalasundaram G, Pieper C, Lischper M, Galla HJ. Regulation of the blood-brain barrier integrity by pericytes via matrix
                    metalloproteinases mediated activation of vascular endothelial growth factor in vitro. Brain Res 2010;1347:1-10.  DOI  PubMed
               145.      Lischper M, Beuck S, Thanabalasundaram G, Pieper C, Galla HJ. Metalloproteinase mediated occludin cleavage in the cerebral
                    microcapillary endothelium under pathological conditions. Brain Res 2010;1326:114-27.  DOI  PubMed
               146.      Feletou M, Vanhoutte PM. Endothelium-derived hyperpolarizing factor: where are we now? Arterioscler Thromb Vasc Biol
                    2006;26:1215-25.  DOI  PubMed
               147.      McNamara CA, Sarembock IJ, Gimple LW, Fenton JW 2nd, Coughlin SR, Owens GK. Thrombin stimulates proliferation of cultured
                    rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 1993;91:94-8.  DOI  PubMed  PMC
               148.      Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-64.  DOI  PubMed
               149.      Garcia JG, Patterson C, Bahler C, Aschner J, Hart CM, English D. Thrombin receptor activating peptides induce Ca2+ mobilization,
                    barrier dysfunction, prostaglandin synthesis, and platelet-derived growth factor mRNA expression in cultured endothelium. J Cell
                    Physiol 1993;156:541-9.  DOI  PubMed
               150.      Lee HY, You HJ, Won JY, et al. Forkhead factor, FOXO3a, induces apoptosis of endothelial cells through activation of matrix
                    metalloproteinases. Arterioscler Thromb Vasc Biol 2008;28:302-8.  DOI  PubMed
   55   56   57   58   59   60   61   62   63   64   65